Multidrug resistance: Clinical relevance in solid tumours and strategies for circumvention

Current Opinion in Oncology

Volumn 10, Issue SUPPL. 1, 1998, Pages

  Kaye, Stanley B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; GLYCOPROTEIN P; MEMBRANE PROTEIN;

CONFERENCE PAPER; CROSS RESISTANCE; HUMAN; MULTIDRUG RESISTANCE; PHARMACOKINETICS; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; RANDOMIZED CONTROLLED TRIALS;

EID: 0031728267     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 435:152-162.
2. Nooter K, Herwijer H: Multidrug resistance in human cancers. Br J Cancer 1991, 63:663-669.
3. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, et al.: Quantitative analysis of mdr1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87:7160-7164.
4. Tew KD, Houghton JA, Houghton PJ: Modulation of P-glycoprotein of P-glycoprotein-mediated multidrug resistance. In: Preclinical and Clinical Modulation of Anticancer Drugs. Boca Raton, FL: CRC Press; 1993:125-196.
5. Chan HS, Thorner PS, Haddad G, Ling V: Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990, 8:689-704.
6. Chan HS, Huddad G, Thorner PS, Deboer G, Lin YP, Ondrusek N, Yeger H, Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991, 325:1608-1614.
7. Pinedo HM, Giaccone G: P-glycoptorein - a marker of cell behavior [editorial]. N Engl J Med 1995, 333:1417-1419.
8. Weinstein R, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, et al.: Relationship of the expression of the mogene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991, 51:2720-2726.
9. Bradley G, Sharma R, Rajalakshmi S, Ling V: P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 1992, 52:5154-5161.
10. Trock BJ, Leonessa F, Clark R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997, 89:917-913.
11. Kaye SB: Multidrug resistance in breast cancer - is the jury in yet? J Natl Cancer Inst 1997, 89:902-903.
12. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993, 85:637-639.
13. Chin KV, Ueda K, Pastan I, Gottesman MM: Modulation of activity of the promoter of the human MDR-1 gene by Ras and p53. Science 1992, 255:459-462.
14. Holzmayer TA, Hilsenbeck S, von Hoff D, Roninson IB: Clinical correlates of MDR-1 gene expression in ovarian and small cell lung carcinoma. J Nat Cancer Inst 1992, 84:1486-1491.
15. Van der Zee AG, Hollena H, de Jong S, Boonstra H, Gouw A, Willemse PHB, Zijlstra JG, de Vries EGE: P-glycoprotein and DNA topoisomerase activity in tumours of the ovary, before and after chemotherapy. Cancer Res 1991, 51:5915-5120.
16. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991, 9:17-24.
17. Ma DDF, Davey RA, Harman DH, Isbister JP, Scurr RD, MacKertich SM, Dowden G, Bell DR: Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet 1987, i:135-137.
18. Dalton WAS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG M, Taylor CW, Miller TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989, 7:415-424.
19. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K: Modulation of multidrug resistance multiple myeloma by cyclosporin. Lancet 1992, 340:255-259.
20. Lum B L, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992, 10:1635-1642.
21. Fisher GA, Hausdorff J, Lum BL, Brophy NA, Duran GE, Ehsan MN, Collins H, Halsey J, Sikic BI: Phase I trial of etoposide with the cyclosporin SDZ PSC 833, a modulator of multidrug resistance. Proc Am Soc Clin Oncol 1994, 13:143.
22. Giaccone G, Linn SC, Catimel G, Vermorken JB, Koier I, Welink J, Vijgh JWF vd, Eeltink C, Laburte C, Pindedo HM: Phase I and pharmacokinetic study of SDZ PSC833 per os in combination with doxorubicin in patients with solid tumours. Proc Am Soc Clin Oncol 1994, 13:142.
23. Egorin M, Fracasso P, Zuhouski E, Daniel F, Kearns C, Fisher G, Collins H, Wiehl J, Pearce T, Charnick S, et al.: Effect of the MDR modulator, SDZ PSC833 on the pharmacokinetic and pharmacodynamics of 3 hr. paclitaxel infusions. Proc Am Soc Clin Oncol 1996, 15:473.
24. Sikic BI: Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993, 11:1629-1635.
25. Rodenburg CJ, Nooter K, Herweijer H, Seynaeve C, Oosterom R, Stoter G, Verweij J: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991, 2:305-306.
26. Verweij J, Herweijer H, Oosterom R, Van der Burg MEL, Planting AST, Seynaeve C, Stoter G, Nooter K: A phase II study of epidoxorubicin in colorectal cancer and use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 1991, 64:361-364.
27. Wishart GC, Plumb JA, Going JJ, McNicol AM, McArdle CS, Tsuruo T, Kaye SB: P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with 2 monoclonal antibodies. Br J Cancer 1990, 62:758-761.
28. Linn SC, Ginccone G, van Diest PJ, Biskhuis W, Pinedo H, Bank J: Prognostic signfiicance of P-glycoprotein expression in breast cancer. Proc Am Soc Clin Oncol 1994, 31:102.
29. Baekelandt M, Covelli A, Trope C, Kristensen G: Phase I/II trial of cisplatin and doxorubicin with SDZ PSC 833 in patients with refractory ovarian cancer. Proc Am Soc Clin Oncol 1997, 16:216a.
30. Fields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Bark S, Gretz H, et al.: SDZ PSC833/paclitaxel in paclitaxel-refractory ovarian carcinoma: a phase II trial with renewed responses. Proc Am Soc Clin Oncol 1997, 16:351a.
31. Milroy R: A randomized clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 1993, 68:813-818.
32. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, et al.: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo controlled randomized trial. J Clin Oncol 1994, 12:1771-1777.
33. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI: Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC833. J Natl Cancer Inst 1995, 87:1593-1602.
34. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Burnol TF, Starling JJ: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996, 56:4171-4179.
35. Bissett D, Graham MA, Setanoians A, Chadwick GA, Wilson P, Koier I, Henrar R, Schwartsmann G, Cassidy J, Kaye SB, et al:. Phase I and pharmacokinetic study of rhizoxin. Cancer Res 1992, 52:2894-2898.
36. Vasey PA, Bissett D, Strolin-Benedetti M, Poggesi I, Breda M, Adams L, Wilson P, Pacciarini MA, Kaye SB, Cassidy J: Phase I clinical and pharmacokinetic study of 3′-deamino-3′-(2-methoxy-4-morpholinyl) doxorubicin (FCE 23762). Cancer Res 1995, 55:2090-2096.
37. Cole SP, Bhardwaj G, Gerlach J, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 1992, 258:1650-1654.